Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: A key factor in controlling hypoxia-selective drug release

Biochemical Pharmacology

Volumn 63, Issue 9, 2002, Pages 1629-1639

  Everett, Steven A ^a   Swann, Elizabeth ^b   Naylor, Matthew A ^a   Stratford, Michael R L ^a   Patel, Kantilal B ^a   Tian, Natasha ^a   Newman, Robert G ^a   Vojnovic, Borivoj ^a   Moody, Christopher J ^b   Wardman, Peter ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EXETER   (United Kingdom)

Author keywords

7 Hydroxy 4 methylcoumarin; Chemical kinetics; Cytochrome P450 reductase; Hypoxia; Indolequinone; MCF 7 breast tumour cells; NADPH; Pulse radiolysis; Reduction; Semiquinone radical

Indexed keywords

5 METHOXY 3 (1 (4 METHYLCOUMARIN 7 YL)OXY 1 (THIOPHEN 2 YL)METHYL 1,2 DIMETHYLINDOLE 4,7 DIONE; 5 METHOXY 3 (1 (4 METHYLCOUMARIN 7 YL)OXY) ETHYL 1,2 DIMETHYLINDOLE 4,7 DIONE; 5 METHOXY 3 (4 METHYLCOUMARIN 7 YL) OXYMETHYL 1,2 DIMETHYLINDOLE 4,7 DIONE; CYTOCHROME P450 REDUCTASE; INDOLE DERIVATIVE; PRODRUG; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION KINETICS; CHROMATOPHORE; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG ELIMINATION; DRUG RELEASE; FLUOROMETRY; HALF LIFE TIME; HUMAN; HUMAN CELL; HYPOXIA; METABOLIC RATE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PULSE RADIOLYSIS; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ANOXIA; COUMARINS; DRUG DELIVERY SYSTEMS; HUMANS; NADPH-FERRIHEMOPROTEIN REDUCTASE; OXIDATION-REDUCTION; OXYGEN; PRODRUGS; TUMOR CELLS, CULTURED;

EID: 0036569920     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(02)00885-7     Document Type: Article

References (48)

1. Mitomycin analogues I. Indolequinones as (potential) bisalkylating compounds
2. Bioreductive drugs for cancer therapy: The search for tumor specificity
3. Bioreductive drugs into the next millennium
4. Radicals from one-electron reduction of nitro compounds, aromatic N-oxides, and quinones: The kinetic basis for hypoxia-selective, bioreductive drugs
5. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases
6. Bioreductive activation of a series of analogues of 5-aziridinyl-1-metyl-2-[1H-indole-4, 7-dione] prop-β-en-α-01 (EO9) by human DT-diaphorase
7. Enzymology of bioreductive drug activation
8. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C
9. The three-dimensional structure of NAD(P)H: Quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: Mechanism of the two-electron reduction
10. Structures of recombinant human and mouse NAD(P)H: Quinone oxidoreductases: Species comparison and structural changes with substrate binding and release
11. EO9: A novel bioreductive alkylating indolequinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models
12. EO9 Phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group
13. Phase I trial with weekly EO9, a novel bioreductive alkylating indolequinone, by the EORTC Early Clinical Study Group (ECSG)
14. Establishment of an isogenic human colon tumor model for NQO1 gene expression: Application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo
15. A new screening system for NAD(P)H: Quinone oxidoreductase (NQO1)-directed antitumor quinones: Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent
16. Reduction of the indolequinone anticancer drug EO9 by purified DT-diaphorase: A detailed kinetic study and analysis of metabolites
17. Relative importance of DT-diaphorase and hypoxia in the bioactivation of EO9 by human lung tumor cell lines
18. The relative importance of NADPH: Cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions
19. Indolequinone antitumor agents: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H: Quinone oxidoreductase, and in vitro cytotoxicity
20. Bioreductive activation of a series of indolequinones by human DT-diaphorase: Structure-activity relationships
21. Indolequinone antitumour agents: Correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H: Quinone oxidoreductase, Part 2
22. Indolequinone bioreductive drugs: Kinetic factors which influence selectivity for hypoxia
23. The autoxidation of the reduced forms of EO9
24. Indolequinone antitumour agents: Reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxo-indol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro
25. Prodrugs for targeting hypoxic tissues: Regiospecific elimination of aspirin from reduced indolequinones
26. Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia
27. Controlling the rates of reductively-activated elimination from the (indol-3-yl)methyl position of indolequinones
28. 2-Cyclopropyl indolequinones and their analogues as bioreductively-activated antitumour agents: Structure-activity in vitro and efficacy in vivo
29. - in aqueous solutions
30. 2 from hydrogen peroxide formation in pulse-irradiated oxygenated water
31. Coomassie blue method of protein quantitation. A simple linear spectrophotometric assay for ≤0.5-50 μg of protein
32. Production of reactive oxygen species by microsomes entiched in specific human cytochrome P450 enzymes
33. Metabolism of diaziquone by NAD(P)H: (Quinone acceptor) oxidoreductase (DT-diaphorase): Role in diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma cells
34. The one-electron reduction potential of several substrates can be related to their reduction rates by cytochrome P-450 reductase
35. Correlation of kinetic parameters of nitroreductase enzymes with redox properties of nitroaromatic compounds
36. Nitroimidazole bioreductive metabolism. Quantitation and characterisation of mouse tissue benznidazole nitroreductases
37. Studies on the mechanisms of thallium-mediated inhibition of hepatic mixed function oxidase activity. Correlation with inhibition of NADPH-cytochrome c (P450) reductase
38. Reductase enzyme expression across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9
39. Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes
40. Fluorescence switching by O-dearylation of 7-arylcoumarins. Development of novel fluorescent probes to detect reactive oxygen species
41. Bioreductive metabolism of the novel flourinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-nitroimidazolyl)acetamide (SR4554)
42. Preclinical development and current status of fluorinated 2-nitroimidazole hypoxia probe N-(2-hydroxy-3,3,3-trifluoropropyl)-2-(2-niro-1-imidazolyl) acetamdide (SR 4554, CRC 94/17): A non-invasive diagnostic probe for the measurement of tumour hypoxia by magnetic resonance spectroscopy and imaging, and positron emission tomography
43. Rates of reductive elimination of substituted nitrophenols from the (indol-3-yl)methyl position of indolequinones
44. Oxygenation of human tumours
45. Enzyme-directed drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolising enzymes, particularly DT-diaphorase
46. The experimental development of bioreductive drugs and their role in cancer therapy
47. Bioreductive mechanisms
48. Mechanisms of action of quinone-containing alkylating agents i: NQO1-directed drug development